Search

This strategic partnership underscores Emcure's commitment to innovative affordable global healthcare Emcure Pharmaceuticals has signed a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, part of California, US based [...]

WASHINGTON, DC -- The following information was released by Public Citizen: Today, Gilead Sciences announced a licensing deal authorizing six generics manufacturers to sell the breakthrough HIV treatment lenacapavir in [...]

Byline: Aaron Gregg; Dan Diamond Pharmaceutical giant GlaxoSmithKline is sidestepping its pledge to lower asthma inhaler prices, a key senator charged Wednesday, in the latest effort by Democrats to pressure [...]

M2 PHARMA-September 16, 2024-Zydus Lifesciences signs licensing and supply agreement with Viwit Pharmaceuticals (C)2024 M2 COMMUNICATIONS India-based pharmaceutical company focused on manufacturing generic drugs Zydus Lifesciences Ltd. announced on Friday [...]

M2 EQUITYBITES-September 16, 2024-Zydus Lifesciences signs licensing and supply agreement with Viwit Pharmaceuticals (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk India-based pharmaceutical company focused on manufacturing generic drugs Zydus Lifesciences Ltd. announced on [...]

Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi (golimumab) Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2506 [...]

ALAMEDA: Exelixis, Inc. (Nasdaq: EXEL) announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement resolves two [...]

ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This [...]

As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval Zydus Lifesciences' [...]

As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval Zydus Lifesciences [...]

Stockholm: Xbrane Biopharma AB has issued the following news release: Partners Xbrane Biopharma AB ('Xbrane') and STADA have entered into an exclusive licensing agreement with US biosimilars specialist Valorum Biologics [...]

Within five years, adolescent girls and women across Africa could be empowered with long-acting anti-HIV injections, virtually eliminating their risk of HIV transmission through sex. This, thanks to ViiV Healthcare, [...]

Luxembourg: Court of Justice of the European Union (General Court) has issued the following Judgment on (12 December 2018): JUDGMENT OF THE GENERAL COURT (Ninth Chamber) 12 December 2018 (*) [...]

China is in talks with Pfizer Inc to secure a licence that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm's COVID-19 antiviral drug [...]

China is in talks with Pfizer Inc to secure a licence that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm's COVID-19 antiviral drug [...]

China is in talks with Pfizer Inc to secure a licence that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm's COVID-19 antiviral drug [...]

Vilnius: J.Molner AS has issued the following news release: J. Molner AS, an Estonia-based pharmaceutical company specializing in the development of innovative generic drugs, announces that it has entered into [...]

Brentford, London, United: GlaxoSmithKline has issued the following press release: ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, together with the [...]

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, together with the Medicines Patent Pool (MPP) announced on 30 Mar 2023 that MPP has signed sublicence agreements with Aurobindo, Cipla and Viatris - through its subsidiary Mylan - to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP). This is enabled by the signing of a voluntary licensing agreement for patents relating to cabotegravir LA for PrEP with MPP in Jul 2022. Only seven months after the first regulatory approval of cabotegravir LA for PrEP in the world by the US Food and Drug Administration (FDA), ViiV Healthcare and MPP signed a voluntary licence agreement in Jul 2022 for patents relating to cabotegravir LA for PrEP to help enable access in all least developed, low-income, lower-middle-income and sub-Saharan African countries. This licence builds on a long-standing partnership between ViiV Healthcare and MPP, which has been highly successful in facilitating the manufacture and sale of generic versions of oral ViiV Healthcare medicines in countries most affected by HIV and least able to pay for treatment and care. Through the MPP-ViiV Healthcare agreement, the selected generic manufacturers will be able to develop, manufacture, and supply generic versions of cabotegravir LA for PrEP, in 90 countries, subject to required regulatory approvals being obtained. Aurobindo and Viatris will manufacture in India; Cipla will manufacture in India and has plans to manufacture in South Africa as well. These three manufacturers were selected through an open call for Expressions of Interest. Compared to oral HIV prevention options, cabotegravir LA for PrEP is more complex to manufacture and ViiV Healthcare is committed to supporting Aurobindo, Cipla and Viatris with technical know-how to enable development and access as soon as possible. MPP, the selected manufacturers and ViiV Healthcare, will continue to work with the Coalition to Accelerate Access to Long-Acting PrEP - convened by the Global Fund, PEPFAR, UNAIDS, Unitaid, and the World Health Organization (WHO) with AVAC as the Secretariat - to find tangible, practical solutions to accelerate rapid and sustainable access to cabotegravir LA for PrEP in low- and middle-income countries. Until a generic version is available, ViiV Healthcare is committed to continuing to work with partners to widen access and supply cabotegravir LA for PrEP at a non-profit price in low-income, least developed and all sub-Saharan African countries. Cabotegravir LA for PrEP is the first and only long-acting injectable antiretroviral (ARV) for which ViiV Healthcare has gained regulatory approval in the US, Australia, Zimbabwe, South Africa and Malawi for use in HIV prevention for at risk adults and adolescents weighing at least 35kg to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test prior to receiving it. ViiV Healthcare has submitted marketing applications in a number of countries including the majority of countries where clinical trials were conducted, with further registrations planned. Original source: GlaxoSmithKline, website: http://www.gsk.com/, Copyright GlaxoSmithKline plc 2023., patents and technical know-how; antiviral agents; cabotegravir; HIV treatments; Aurobindo; Cipla; GSK; Mylan; Pfizer; Shionogi; Viatris; ViiV [...]

First Generic of Abraxane in Korea, World 4th Commercial Scale-Up Global tech-transfer expected to US, Japan, and Europe SEONGNAM, South Korea, Jan. 26, 2023 /PRNewswire/ -- SN BioScience (CEO Park [...]

New York: Orion Oyj has issued the following news release: Orion and Amneal enter strategic partnership - Orion receives exclusive licence to commercialise Amneal's generic products in Europe, Australia and [...]

BRIDGEWATER: AMNEAL PHARMACEUTICALS, INC. has issued the following news release: Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ('Amneal' or the 'Company') today announced it has signed a long-term license agreement with Orion [...]

ORION CORPORATION PRESS RELEASE 4 JANUARY 2023 at 16.00 EET Orion and Amneal enter strategic partnership - Orion receives exclusive licence to commercialise Amneal's generic p roducts in Europe, Australia [...]

- Long-term collaboration to bring Amneal generic products to market in Europe, Australia, and New Zealand BRIDGEWATER, N.J. -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ('Amneal' or the 'Company') today announced [...]

(GLOBE NEWSWIRE via COMTEX) -- ORION CORPORATION PRESS RELEASE 4 JANUARY 2023 at 16.00 EET Orion and Amneal enter strategic partnership - Orion receives exclusive licence to commercialise Amneal's generic [...]

Strides Pharma Science announced a sub-license agreement with Medicines Patent Pool (MPP) to commercialize a generic version of Pfizer's COVID-19 oral treatment in 95 low and middle-income markets. Developed by [...]

GENEVA: Medicines Patent Pool has issued the following news release: On the side lines of the World Cancer Congress, the Medicines Patent Pool (MPP) today announced the signing of a [...]

Pharmaceutical giant Novartis has signed a licensing agreement increasing access to a vital leukaemia treatment, a UN-backed public health organisation said Thursday, marking the first-ever such agreement for a cancer [...]